EUVIMEDEUVIMED entdecken
MetaanalyseRandomisierte kontrollierte StudieOpen Access

Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure

Dapagliflozin bei wegen Herzinsuffizienz hospitalisierten Patient:innen: Primärergebnisse der randomisierten klinischen Studie DAPA ACT HF-TIMI 68 und Metaanalyse von SGLT2-Inhibitoren

David D Berg iD, Siddharth M Patel iD, Paul M Haller iD, Abby L Cange, Michael G Palazzolo iD, Andrea Bellavia iD, Julia F Kuder, Akshay S Desai iD, Silvio E Inzucchi iD, John J V McMurray iD, Eileen O'Meara iD, Subodh Verma iD und 17 weitere

Circulation · 18.11.2025 · 152 (20) · 1411-1422

DOI: 10.1161/circulationaha.125.076575 ↗

Auf einen Blick

Bei 2.401 wegen Herzinsuffizienz hospitalisierten Patient:innen senkte ein in der Klinik begonnener Dapagliflozin-Einsatz das kombinierte Risiko für kardiovaskulären Tod oder Verschlechterung der Herzinsuffizienz bis 2 Monate nicht signifikant.

Fragestellung

Wirkt ein in der Klinik begonnener Dapagliflozin-Einsatz bei hospitalisierten Patient:innen mit Herzinsuffizienz auf kardiovaskulären Tod oder Verschlechterung der Herzinsuffizienz innerhalb von 2 Monaten?

Methode

Randomisierte, doppelblinde, placebokontrollierte Studie zu Dapagliflozin 10 mg täglich; primärer Endpunkt bis 2 Monate. Zusätzlich präspezifizierte Metaanalyse randomisierter Studien zu SGLT2-Inhibitoren bei hospitalisierten HF-Patient:innen.

Ergebnisse

2401 Patient:innen; 1218 Dapagliflozin, 1183 Placebo. Primärer Endpunkt: 10,9 % vs. 12,7 %; HR 0,86 (95 %-KI 0,68–1,08; P=0,20). Metaanalyse: HR 0,71 (95 %-KI 0,54–0,93) für kardiovaskulären Tod oder Verschlechterung der HF.

Schlussfolgerung der Autor:innen

In dieser Studie reduzierte der klinische Beginn von Dapagliflozin das Risiko für kardiovaskulären Tod oder Verschlechterung der Herzinsuffizienz bis 2 Monate nicht signifikant. Die Gesamtheit der randomisierten Daten spricht jedoch für einen möglichen frühen Nutzen von SGLT2-Inhibitoren.

Kernaussagen

  • Primärer Endpunkt unter Dapagliflozin nicht signifikant reduziert
  • Metaanalyse zeigte geringeres frühes Risiko unter SGLT2-Inhibitoren
  • Symptomatische Hypotonie und Nierenfunktion wurden als Sicherheit erfasst

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Metaanalyse in der Zeitschrift Circulation, erschienen am 18.11.2025. Verfasst von David D Berg und 28 weiteren Autor:innen. Beteiligte Einrichtung: TIMI Study Group, Brigham and Women's Hospital, Boston, MA (D.D.B., S.M.P., P.M.H., A.L.C., M.G.P., A.B., J.F.K., C.T.R., M.L.O., S.A.M., M.S.S.). Hauptthemen laut MEDLINE: Benzhydryl Compounds, Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Glucosides. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, AstraZeneca.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: SGLT2 (sodium-glucose cotransporter-2) inhibitors reduce the risk of cardiovascular death or worsening heart failure (HF) in outpatients with HF. Data on initiation in patients hospitalized for HF are limited. METHODS: We conducted a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of in-hospital initiation of dapagliflozin (10 mg daily) in patients hospitalized for HF. The primary efficacy outcome was a composite of time to cardiovascular death or worsening HF through 2 months. Key safety outcomes included symptomatic hypotension and worsening kidney function. A prespecified meta-analysis of randomized trials evaluating initiation of SGLT2 inhibitors in patients hospitalized for HF was performed. RESULTS: Of 2401 patients (median age, 69 [Q1–Q3, 58–77] years, 815 [33.9%] women, 448 [18.7%] Black race, 1717 [71.5%] left ventricular ejection fraction ≤40%, 1074 [44.7%] newly diagnosed HF) randomized between September 2020 and March 2025, 1218 were assigned to dapagliflozin and 1183 to placebo. The primary outcome occurred in 133 patients (10.9%) in the dapagliflozin group and 150 (12.7%) in the placebo group (hazard ratio [HR], 0.86 [95% CI, 0.68–1.08]; P =0.20). A worsening HF event occurred in 115 (9.4%) and 122 (10.3%) patients in the dapagliflozin and placebo groups, respectively (HR, 0.91 [95% CI, 0.71–1.18]). Cardiovascular death occurred in 30 (2.5%) and 37 (3.1%) patients (HR, 0.78 [95% CI, 0.48–1.27]), and death from any cause occurred in 36 (3.0%) and 53 (4.5%) patients in the dapagliflozin and placebo groups, respectively (HR, 0.66 [95% CI, 0.43–1.00]). The rates of symptomatic hypotension were 3.6% and 2.2%, and the rates of worsening kidney function were 5.9% and 4.7% with dapagliflozin and placebo, respectively. In a meta-analysis of patients hospitalized for HF, SGLT2 inhibitors reduced the early risk of cardiovascular death or worsening HF (HR, 0.71 [95% CI, 0.54–0.93] P =0.012) and of all-cause death (HR, 0.57 [95% CI, 0.41–0.80]; P =0.001). CONCLUSIONS: In this trial, in-hospital initiation of dapagliflozin did not significantly reduce the risk of cardiovascular death or worsening HF through 2 months in hospitalized HF patients. However, the totality of randomized clinical trial data suggests that in-hospital initiation of SGLT2 inhibitors may reduce the early risk of cardiovascular death or worsening HF and of all-cause mortality. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04363697.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsHeart FailureGlucosidesHospitalizationHumansMaleFemaleAgedMiddle AgedDouble-Blind MethodTreatment Outcome

Stichwörter der Autor:innen

hospitalizationrandomized clinical trialsodium-glucose cotransporter 2 inhibitorsworsening heart failure.

Substanzen

Benzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsdapagliflozinGlucosides

Autor:innen und Institutionen

  • TIMI Study Group, Brigham and Women's Hospital, Boston, MA (D.D.B., S.M.P., P.M.H., A.L.C., M.G.P., A.B., J.F.K., C.T.R., M.L.O., S.A.M., M.S.S.).
  • Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (D.D.B., S.M.P., P.M.H., A.L.C., M.G.P., A.B., J.F.K., A.S.D., C.T.R., M.L.O., S.A.M., M.S.S., S.D.W.).
  • Department of Cardiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (P.M.H.).
  • Section of Endocrinology, Yale University School of Medicine, New Haven, CT (S.E.I.).
  • British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom (J.J.V.M.).
  • Department of Cardiology, Université de Montréal, Montreal, Canada (E.O.).

ORCID-Profile: David D Berg, Siddharth M Patel, Paul M Haller, Michael G Palazzolo, Andrea Bellavia, Akshay S Desai, Silvio E Inzucchi, John J V McMurray, Eileen O'Meara, Subodh Verma, Jan Bělohlávek, Jarosław Drożdż, Béla Merkely, Modele O Ogunniyi, Joseph L Izzo, Christian T Ruff, Michelle L O'Donoghue, Sabina A Murphy, Marc S Sabatine, Stephen D Wiviott

Förderung

  • NCATS NIH HHS
  • AstraZeneca

Zitieren

APA

Berg, D. D., Patel, S. M., Haller, P. M., Cange, A. L., Palazzolo, M. G., Bellavia, A., Kuder, J. F., Desai, A. S., Inzucchi, S. E., McMurray, J. J. V., O'Meara, E., Verma, S., Bělohlávek, J., Drożdż, J., Merkely, B., Ogunniyi, M. O., Drasnar, T., Izzo, J. L., Sarman, B., …, & DAPA ACT HF-TIMI 68 Trial Committees and Investigators (2025). Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure. Circulation, 152(20), 1411-1422. https://doi.org/10.1161/circulationaha.125.076575

Vancouver

Berg DD, Patel SM, Haller PM, Cange AL, Palazzolo MG, Bellavia A, et al. Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure. Circulation. 2025;152(20):1411-1422. doi:10.1161/circulationaha.125.076575

BibTeX
@article{Berg2025,
  author = {Berg, David D and Patel, Siddharth M and Haller, Paul M and Cange, Abby L and Palazzolo, Michael G and Bellavia, Andrea and Kuder, Julia F and Desai, Akshay S and Inzucchi, Silvio E and McMurray, John J V and O'Meara, Eileen and Verma, Subodh and Bělohlávek, Jan and Drożdż, Jarosław and Merkely, Béla and Ogunniyi, Modele O and Drasnar, Tomáš and Izzo, Joseph L and Sarman, Balazs and McGinty, John E and Ramanathan, Krishnan and Mulkay, Angel J and Przybylski, Andrzej and Ruff, Christian T and O'Donoghue, Michelle L and Murphy, Sabina A and Sabatine, Marc S and Wiviott, Stephen D and DAPA ACT HF-TIMI 68 Trial Committees and Investigators, DAPA ACT HF-TIMI 68 Trial Committees and Investigators},
  title = {Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure},
  journal = {Circulation},
  year = {2025},
  volume = {152},
  number = {20},
  pages = {1411--1422},
  doi = {10.1161/circulationaha.125.076575}
}
Kostenlos starten →